Key Highlights
● Celldex is discontinuing barzolvolimab in atopic dermatitis.
● A Phase 2 study missed its primary endpoint of itch reduction at Week 16.
● The chronic spontaneous urticaria program continues.
● A Biologics License Application is planned for 2027.
Celldex Therapeutics (NASDAQ:CLDX) said it will stop developing barzolvolimab in atopic dermatitis after a Phase 2 study missed its main itch goal, while keeping its hives program on track.
The trial result
Celldex Therapeutics said on Thursday, November 19, that it is discontinuing development of barzolvolimab in atopic dermatitis. The decision followed a Phase 2 study that missed its primary endpoint, a measure of itch reduction at Week 16.
The study tested two doses, 300 mg and 150 mg, against placebo. Patients on the higher dose saw itch scores fall by more than those on placebo, but not by enough to meet the endpoint. Patients on the lower dose fared worse than placebo on that measure. In a trial, a primary endpoint is the main goal a drug must hit for the study to count as a success, so missing it usually ends or reshapes a program.
What barzolvolimab does
Barzolvolimab is an experimental antibody therapy that Celldex has been testing in more than one condition. A setback in one disease does not determine results in another, because each condition has its own biology and its own trial endpoints.
Atopic dermatitis, the most common form of eczema, is a chronic skin condition marked by intense itching and driven by a broad mix of immune pathways. The Phase 2 result shows the drug did not deliver the itch relief Celldex was looking for in that disease.
The program that continues
The setback does not end the drug's story. Celldex said its program in chronic spontaneous urticaria, or CSU, will continue, with a Biologics License Application planned for 2027. CSU is a condition in which patients suffer recurring hives and itching without an obvious external trigger.
With the atopic dermatitis work ending, the CSU program now carries the drug's prospects. Dropping that indication narrows the potential market, but it also lets the company concentrate its resources on the hives program it plans to file.
A rough day for biotech and the market
The news came as the broader market fell sharply. The Russell 2000 dropped 59.20 points to 2,655.11, and the S&P SmallCap 600 closed at 1,635.57, the worst of the major indexes. The S&P 500 lost 147.80 points to 7,175.83, a sixth straight decline. The Dow lost 1,101.11 points to close below 50,000.
Health care was among the weaker S&P sectors. There were bright spots in biotech, though: Insmed (NASDAQ:INSM) jumped after an unconfirmed media report that Sanofi (NASDAQ:SNY) was studying a potential acquisition, with no agreed deal, and SELLAS Life Sciences (NASDAQ:SLS) had soared earlier in the week on Phase 3 data. Small, research-stage biotech companies tend to swing on trial results, often by large amounts, because so much of their value rests on a few programs.
What to watch
Attention now turns to the CSU program and the path toward the planned 2027 filing. Investors will look for further data, regulatory updates and any change in timelines. Celldex's spending plans and cash runway will also be watched as it concentrates on fewer programs. Against a fragile market, the stock will continue to trade on clinical news and on the broader mood of the Russell 2000.






Please wait processing your request...